EYECARE Three-Year Clinical Study Data Shows SightGlass Vision Spectacles Slow Myopia Progression in Children By Staff Tuesday, October 25, 2022 12:24 AM LOS ALTOS, Calif.—SightGlass Vision reported that an analysis of 36-month data from the pivotal CYPRESS myopia control clinical trial has demonstrated the safety and efficacy of SightGlass Vision spectacle lenses with Diffusion Optics Technology for children ages six to 10 years at enrollment. The intervention significantly reduced both axial length and cycloplegic SER progression versus the control, the company said. Lenses that incorporate SightGlass Vision Diffusion Optics Technology use thousands of micro-dots that softly scatter light to reduce contrast on the retina and are designed to reduce myopia progression in children.The results of the study, “Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years” (Laughton, D et al) will be presented at the 2022 American Academy of Optometry annual meeting in San Diego on Thursday, October 27. In addition to illustrating myopia control efficacy, 36-month data showed low device-related adverse event rates. No serious adverse events were reported. Visual performance for distance and near was excellent (20/20 or better) and remained stable, and low contrast visual acuity was similar to control. While the lens proved beneficial at all ages, the slowing of myopia progression among children ages six to seven years at the initiation of treatment is of particular note. “There are currently no other interventions with this degree of demonstrated efficacy for six- and seven-year-old children, even though more severe adult myopia is generally linked to earlier onset,” said Andrew Sedgwick, CEO of SightGlass Vision. “We purposefully enrolled a subset of younger children to examine this gap in myopia control research and treatment options. With its unique mechanism of action, our Diffusion Optics Technology is a new approach and represents a first line of defense for young myopes.” CYPRESS has been recognized for its rigor, designed as a prospective, randomized, controlled, subject and observer masked, multi-site, diverse study population reflecting the U.S. population, three-arm parallel group clinical trial. During the paper presentation, researchers will also share early observations from the CYPRESS extension study, which tracks clinical results beyond the 36-month mark. DOT 0.2 spectacle lenses are not approved in the U.S. Founded in 2016, SightGlass Vision now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.